1-3 of 3
José Javier Sánchez
Close
Sort by
Journal Articles

Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain.

Eva González-Barca, Miguel Canales, MD, PhD, María Jesús Vidal, Albert Oriol, Antonio Salar, Joan Bargay, Montse Cortés, Juan Coya, José Francisco Tomás, Andrés López, José Javier Sánchez, Eva Donato, Andrés Llorente, Secundino Ferrer, Dolores Caballero
Journal: Blood
Blood (2010) 116 (21): 2793.
https://doi.org/10.1182/blood.V116.21.2793.2793
Published: 2010
Journal Articles

Feasability and Toxicity After Induction Treatment with Rituximab-HCVAD and Metotrexate/Citarabine, Followed by Consolidation with Y-90 Ibritumomab Tiuxetan (Phase II GELTAMO–LCM 04-02 study).

Reyes Arranz, Ana Garcia-Noblejas, MD, Carlos Grande, José Terol, Ma, José Javier Sánchez, Javier Perez-Calvo, MD, Miguel Canales, Jose Antonio García-Marco, MD, PhD, Eva Marti, Eulogio Conde, MD, Antonio Salar, MD, PhD, Dolores Caballero
Journal: Blood
Blood (2009) 114 (22): 1703.
https://doi.org/10.1182/blood.V114.22.1703.1703
Published: 2009
Journal Articles

Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain.

Eva Gonzalez-Barca, Miguel Canales, Antonio Salar, Albert Oriol, María Jesús Vidal, Joan Bargay, Montse Cortés, J. Coya, Jose Francisco Tomas, Andrés López, José Javier Sánchez, Eva Donato, Andrés Llorente, Secundino Ferrer, Dolores Caballero
Journal: Blood
Blood (2009) 114 (22): 3692.
https://doi.org/10.1182/blood.V114.22.3692.3692
Published: 2009